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ABSTRACT
Tuberous Sclerosis is a genetic disorder that causes benign tumours to form in the
kidneys, brain, skin, and other organs. This disease is caused by inactivating mutations in
either the TSC1 or TSC2 gene encoding for Hamartin and Tuberin, respectively.
Mechanistically, Hamartin and Tuberin form a tumour suppressor complex by negatively
regulating the mTORC1 pathway and inhibiting protein synthesis. Our lab has
characterized how Tuberin regulates the G2/M transition through binding to and
controlling the localization of Cyclin B1 (Cyc B1). We have determined that
phosphorylation of five key residues in the cytoplasmic retention sequence (CRS) of Cyc
B1 decreases this binding interaction and permits the accumulation of Cyc B1 in the
nucleus and mitotic onset to occur. We have developed two fluorescent systems to monitor
the regulation of mitotic onset by the Tuberin/Cyc B1 complex; Cyc B1 GFP tagged CRS
variants and a fluorescent HEK-293 cell line which contains an iRFP 720 tag inserted into
the genomic DNA at the amino terminus and carboxy terminus of Tuberin. These tools will
be fundamental in studying the formation of this protein complex and the role of Tuberin
in other cellular pathways.
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INTRODUCTION
I.

The Cell Cycle and Control Mechanisms
The cell cycle is a highly regulated process in which cells grow and divide. There

are two stages, interphase and mitosis. Interphase is further subdivided into gap phases
(G1-G2) and DNA duplication (S). Mitosis is the division of the cell into two identical
daughter cells (Norbury and Nurse, 1992; Pines, 1999). There are five stages of mitosis,
the first being prophase with the breakdown of the nuclear envelope and the condensation
of chromatin. The chromosomes then align at the mitotic spindle during metaphase, then
separate to opposite poles at anaphase. Lastly, the chromosomes decondense, the nuclear
membranes reform and the cells separate in telophase and cytokinesis.
Checkpoints between the transition of each phase ensure that the cell satisfies
particular criteria before proceeding. Four well-characterized checkpoints ensure cell size
control, DNA damage response, DNA replication, and proper mitotic spindle formation
(Barnum and O’Connell, 2014). Cell size control is crucial in maintaining cell size in
subsequent generations of daughter cells and maintaining organ size in multicellular
organisms. The DNA damage response and DNA replication checkpoints prevent
mutations from being passed onto daughter cells, while the spindle assembly checkpoint
ensures that the proper number of chromosomes are distributed to each daughter cell. The
timing of the checkpoints differs between different organisms. In mammals, the first
checkpoint is in late G1, and checks for proper cell size, sufficient growth factors and DNA
damage. The second checkpoint is in S phase, which determines whether DNA replication
has occurred faithfully. Another checkpoint is located prior to the G2/M transition, which
also checks for proper cell size, growth factors and DNA damage. The last checkpoint is
1

the spindle assembly checkpoint, also known as the metaphase-to-anaphase transition. This
is when the chromosomes are prevented from separating to opposite poles (anaphase) until
each one is properly attached to the spindle. After the completion of each cell cycle, the
cell ensures that the environment has sufficient nutrients to support its growth before
committing to the cell cycle again and entering G1 phase, if not, it enters quiescence or G0
(Vermeulen et al., 2003).
Progression through the stages of the cell cycle and regulation of the checkpoints
is spatially and temporally regulated by a family of serine-threonine protein kinases that
contain a regulatory subunit (cyclins) and the catalytic subunit (cyclin-dependent kinases
(CDKs)) (Morgan, 1995; Pines, 1995). CDK protein levels are maintained constantly
throughout the cell cycle. While cyclins protein levels change as the cell transitions
between each phase. Classically, there are four types of cyclins: Cyclin D, Cyclin E, Cyclin
A, and Cyclin B. These cyclin-CDK complexes phosphorylate many downstream
substrates. Early entry into G1 is promoted by Cyclin D and CDK4/CDK6 complex (Sherr
and Roberts, 1999). Transition between G1 and S is controlled by the Cyclin E-CDK2
complex and the Cyclin A-CDK2 complex (Ohtsubo et al., 1995; Woo and Poon, 2003).
Cyclin A also binds to CDK1 to transition the cell into mitosis in addition to the main G2/M
transition complex of Cyclin B1-CDK1 (Arellano and Moreno, 1997). The kinase activity
of these complexes is regulated by the presence/absence of the cyclin component and by
inhibitory and activating phosphorylation events on CDKs. When cyclin is not bound, the
CDK active site is blocked by the T-loop, and the CDK is inactive (Jeffrey et al., 1995).
The regulatory phosphorylation sites on CDKs are located on conserved tyrosine (Tyr) and
threonine (Thr) residues. CDK1 is inactivated when Thr14 and Tyr15 are phosphorylated
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by Myt1 and Wee1 kinases, respectively. Dephosphorylation of these two residues by
Cdc25 leads to ATP binding and CDK activation (Lew and Kornbluth, 1996). Upon cyclin
binding to the CDK, CDK-activating kinases (CAKs), phosphorylate a conserved threonine
residue within the T-loop. This causes a conformational change that leads to enhanced
cyclin binding and full activation of the cyclin-CDK complex.
Another level of regulatory control of the cell cycle is enacted by CDK inhibitor
(CKI) proteins that negatively regulate the activity of cyclin-CDK complexes. There are
two major families of CKIs, the INK4 family and the CIP/KIP family (Besson et al., 2008).
The INK4 protein family binds to CDK 4/6 at G1 preventing the CDKs from binding to
Cyclin D; proteins in this family includes p16INK4a, p18INK4c, and p19INK4d (Sherr and
Roberts, 1999). The CIP/KIP family of proteins binds to the cyclin-CDK complexes and
blocks the ATP region of the CDK to inhibit their activity (Russo et al., 1996). There are
three proteins in this family, p21cip1/waf1, p27kip1, and p57kip2, that inhibit the activity of
CDK1 and CDK2, ultimately blocking the transition from G1 to S phase.
Cyclin binding to CDK is mediated by a universally conserved domain, known as
the cyclin box (Figure 1). The synthesis and degradation of cyclins are tightly controlled,
with their levels fluctuating during the cell cycle, with the exception of Cyclin D. The
degradation of the cyclins is mediated by the ubiquitin proteolysis pathway. Cyclins A and
B are tagged for degradation in its degradation box (D-box) (Glotzer et al., 1991), while
cyclin D and E are recognized by a segment rich in proline, glutamic acid, serine, and
threonine residues, also known as the “PEST” sequence (Rechsteiner and Rogers, 1996).
Spatial regulation of the cell cycle is achieved by the subcellular localization and
accumulation of the cyclin-CDK complex. Cyclin B1, the G2/M cyclin, is first detected at
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S phase, when protein levels gradually increase and peak at twice the amount at prophase
and metaphase, and then significantly declines at the start of anaphase through degradation
by the cyclosome/anaphase-promoting complex (APC) (Murray and Kirschner, 1989;
Murray et al., 1989; Holloway et al., 1993; Sudakin et al., 1995). Throughout S phase and
before mitosis, Cyclin B1 is constantly translocating between the cytoplasm and nucleus,
but the rate of nuclear export is greater than the rate of nuclear import, thus resulting in
accumulation in the cytoplasm, until phosphorylation occur on Cyclin B1’s cytoplasmic
retention sequence (CRS) allow it to accumulate in the nucleus (Yang et al., 1998).
II.

Cyclin B1-CDK1 Activation at the G2/M transition
The human Cyclin B1 gene, CCNB1, is located on chromosome 5q13.2 and

encodes for a 62 kDa protein (Sartor et al., 1992). The Cyclin B1-CDK1 complex is
extremely important in catalyzing the onset of mitosis by initiating chromosome
condensation, nuclear envelope breakdown, and mitotic spindle assembly (Lindqvist et al.,
2009). Unlike other cyclins, cyclin B1, does not have a classical nuclear localization
sequence (NLS), instead it is the CRS that when deleted causes nuclear accumulation
(Pines and Hunter, 1994; Moore et al., 1999). The phosphorylation status of five key serine
residues including S116, S126, S128, S133, and S147, dictates the localization of Cyclin
B1 (Figure 1). (Li et al., 1997; Hagting et al., 1998; Yang et al., 1998, 2001; Walsh et al.,
2003). The nuclear export sequence (NES) lies within the CRS and is recognized and bound
by exportin protein chromosome region maintenance 1 (CRM1) to cause nuclear export.
Currently, it is unknown what upstream kinase phosphorylates S116. However, S126 and
S128 are phosphorylated by CDK1 upon Cyclin B1 binding and has also been shown to be
phosphorylated by Erk (Yuan et al., 2002). Principally, Plk1 is found to phosphorylate
4

S147, but it can also phosphorylate the non-canonical residue, S133 if Erk has
phosphorylated S126 and S128 (Toyoshima-Morimoto et al., 2001). The nuclear import of
Cyclin B1 is mediated by Cyclin F and Importin ß. Cyclin F can bind to Cyclin B1 via the
CRS, and overexpression of Cyclin F also causes Cyclin B1 nuclear localization (Kong et
al., 2000). Cyclin B1 can bind directly to the import receptor, Importin ß, and its
immunodepletion causes a decrease in Cyclin B1 nuclear import (Moore et al., 1999;
Takizawa and Morgan, 2000). As mentioned previously, the shuttling of Cyclin B1 is
constant until approximately 5 minutes before nuclear envelope breakdown, at which
Cyclin B1 is rapidly localized to the nucleus (Gavet and Pines, 2010a, 2010b). This switchlike nuclear accumulation of Cyclin B1-CDK1 complex is facilitated by spatial positive
feedback as nuclear localization leads to increased autophosphorylation of the complex by
CDK1. In summary, Cyclin B1 is a highly spatially regulated protein whose localization is
essential in regulating the G2/M transition.

5

Figure 1: Schematic of the Cyclin B1 protein and its key domains.
Starting from the N-terminus to the C-terminus is the Destruction Box (D-box), the Nuclear
Export Sequence (NES) located in the Cytoplasmic Retention Sequence (CRS), and the
Cyclin Box. The D-box confers protein stability and acts as a signal for ubiquitination by
the APC. The NES binds cyclin B1 to its exportin receptor, CRM1, and contains 5 serine
residues that regulate Cyclin B1 trans-localization. The Cyclin Box is responsible for its
binding to its kinase, CDK1. Residues S126 and S128 are known to be phosphorylated by
CDK1, and S133 and S147 are putative Plk1 phosphorylation sites. (Adapted from (Porter
and Donoghue, 2003). Created with BioRender.com.
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III.

Tuberin Integrates Growth Factor and Energy Signaling to Regulate
Cell Growth and Proliferation
Commitment to enter the cell cycle is initiated once there are sufficient nutrients

available in the cellular environment to support the cell’s growth and division. Checkpoints
throughout the cell cycle also ensure that the cell has grown to a particular size before
transition to the next phase. A mediator is required to receive inputs from the cell’s
environment and relay that information to initiate the biosynthesis pathways that are
required for the cell to grow. Tuberin is a tumour suppressor protein that integrates various
nutrient, stress, and growth factors pathways to regulate protein synthesis, cell growth and
proliferation (Figure 2 and 3) (Huang and Manning, 2008). It is encoded by the TSC2 gene
located on chromosome 16p13.3 consisting of 41 exons, of which 40 exons encode a 5.4
kb mRNA transcript (European Chromosome 16 Tuberous Sclerosis Consortium, 1993;
Rosner et al., 2008). Tuberin is an 1807 amino acid protein with a molecular weight of 200
kDa. Its structural and functional domains include a Hamartin binding domain (aa 1 -418);
two small, coiled coil domains (aa 346-371; aa 1008-1021); a leucine zipper motif (aa 75107); a Cyclin B1 binding domain (aa 600-746); a C-terminal GTPase activating protein
(GAP) homology domain (aa 1517 -1674) and a calmodulin binding domain (aa 17401758) (Rosner et al., 2008) (Figure 3).
Tuberin associates in a complex with Hamartin, a 130 kDa protein encoded by the
TSC1 gene located on chromosome 9q34 with 23 exons (van Slegtenhorst et al., 1997,
1998). Tuberin and Hamartin, along with the recently identified TBC1 Domain Family
Member 7 (TBC1D7), are together known as the Tuberous Sclerosis Complex-TBC1D7
(TSC-TBC) complex and function to negatively regulate cell growth and proliferation

7

through the activity of Tuberin’s GAP domain (Nellist et al., 1999; Tee et al., 2002, 2003;
Dibble et al., 2012). Hamartin is known to stabilize Tuberin by preventing its interaction
with the HERC1 (HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase Family
Member 1), ubiquitin ligase that tags Tuberin for degradation (Benvenuto et al., 2000;
Chong-Kopera et al., 2006). Tuberin acts as a chaperone protein for Hamartin (Nellist et
al., 1999) and TBC1D7 further stabilizes the Tuberin-Hamartin interaction (Dibble et al.,
2012).
Drosophila genetic screens for regulators of organ growth were the first studies
that determined the function of D. melanogaster Tuberin ortholog, gigas (Gao and Pan,
2001; Potter et al., 2001; Tapon et al., 2001). They found that mutations in the Drosophila
Tsc1 gene and the gigas gene, the homologue of TSC2, caused not only an eye-overgrowth
phenotype, but an increase in cell proliferation and cell size. This led to the discovery that
upstream, TSC was inhibited by the Insulin-like Growth Factor (IGF) and the serine
threonine kinase, Akt pathway. The IGF-1/Akt pathway is activated when insulin or IGF
bind and transactivate the IGF transmembrane receptors (IGFR), causing insulin receptor
substrate (IRS) recruitment to activate phosphoinositide 3-kinase (PI3K), that allows for
the recruitment and activation of phosphoinositide dependent kinase-1 (PDK1) to the
membrane. Finally, PDK1 can activate Protein Kinase B (Akt) (Hemmings and Restuccia,
2012). Akt negatively regulates Tuberin through phosphorylation of the S939 and T1462
residues and causes the dissociation of Tuberin and Hamartin (Inoki et al., 2002; Manning
et al., 2002; Potter et al., 2002).
Tuberin also integrates growth factor signaling via the extracellular-signalregulated kinase1/2-p90 ribosomal protein S6 kinase (ERK1/2-RSK) pathway. In this
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pathway, binding of epidermal growth factor (EGF) to the transmembrane associated
epidermal growth factor receptor (EGFR) causes a signaling cascade that activates ERK
via phosphorylation which then activates (ribosomal S6 kinase) RSK (Cargnello and Roux,
2011). RSK can phosphorylate Tuberin at S1798 and also weakly phosphorylate the Akt
sites S939 and T1462 (Roux et al., 2004). Erk can also directly phosphorylate the Tuberin
residues of S540 and S664, causing decreased binding affinity to Hamartin and significant
increases in cell proliferation (Ma et al., 2005, 2007).
Lastly, nutrients are converted to cellular energy in the form of Adenosine
triphosphate (ATP). The AMP-dependent protein kinase (AMPK) pathway is a central
regulator of cellular metabolism and senses the amount of intracellular ATP production. In
poor nutrient conditions, decreases in ATP production cause an increase in intracellular
adenosine diphosphate (ADP) and adenosine monophosphate (AMP). AMPK acts as a
sensor for the cellular ADP and AMP levels and is activated to phosphorylate a number
of substrates involved in cellular metabolism and growth (Mihaylova and Shaw, 2011).
Namely, in low nutrient conditions, AMPK directly phosphorylates Tuberin at S1387 and
T1271, with the first residue resembling more of an AMPK consensus site (Inoki et al.,
2003b). The phosphorylation of Tuberin on the AMPK consensus site also primes GSK3ßmediated phosphorylation of Tuberin at S1337 and S1341, leading to activation of the TSC
(Mak et al., 2003; Inoki et al., 2006). The many post-translational modifications on
Tuberin have a significant effect on its ability to modulate cellular growth and proliferation.
The canonical function of Tuberin is through the TSC/Rheb/mTORC1 pathway.
The direct substrate of Tuberin’s GAP activity is the Ras family GTPase, Ras homolog
enriched in brain (Rheb) (Inoki et al., 2003a; Tee et al., 2003; Zhang et al., 2003). Rheb is
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a small GTPase that converts between the active form, Rheb-GTP, and the inactive form,
Rheb-GDP. Intrinsically, Rheb has a low GTPase activity and the activation of GTPase by
Tuberin results in the conversion of active Rheb to inactive Rheb (Im et al., 2002) which
is unable to activate the mammalian Target of Rapamycin (mTOR). Thus, Tuberin acts as
a negative regulator of mTORC1.
mTOR is a serine/threonine-protein kinase and is the master regulator of protein
synthesis, cell growth and metabolism (Saxton and Sabatini, 2017). It is the catalytic
subunit of two distinct complexes, mTOR Complex 1 (mTORC1) and mTOR Complex 2
(mTORC2). The key difference in the composition of these two complexes is that
mTORC1 contains a rapamycin-sensitive protein, regulatory protein associated with
mTOR (Raptor) which is a rapamycin-sensitive protein, while mTORC2 contains the
rapamycin insensitive companion of mTOR (Rictor) (Jacinto et al., 2004). Another key
difference is the role of TSC in the regulation of these two complexes. TSC downregulates
mTORC1 while is required for the proper activation of mTORC2 by Tuberin’s direct
interaction with Rictor (Oh and Jacinto, 2011). Functionally, mTORC1 is known to
promote cell growth by controlling the synthesis of proteins, lipids, and nucleotides while
inhibiting autophagy. It controls protein synthesis via the regulation of p70S6 Kinase 1
(S6K1) and 4E binding protein 1 (4E-BP1) (Wullschleger et al., 2006). mTORC2’s role in
the cell include actin cytoskeleton reorganization and cell migration but increasing
evidence also suggests mTORC2 performs mTORC1 functions such as protein synthesis
and maturation, and autophagy (Oh and Jacinto, 2011).
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Figure 2: Schematic of key proteins that regulate Tuberin protein signaling.
Created with BioRender.com
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Figure 3: Schematic of protein domains and phosphorylation sites on Tuberin.
The structural domains of Tuberin are: a leucine zipper region (LZ) from residues 75 -107; two
coiled-coil regions (CC) on residues 346-371 and residues 1008-1021; a GTPase activating protein
domain (GAP) on residues 1517 -1674, and a From N to C terminus, the Hamartin binding domain
(residues 1-418), the HERC1 binding domain (residues 1-608), CyclinB1 binding domain (pink)
(residues 600-746), the Rheb binding domain (residues 965-1807), and CaM, Calcium/Calmodulin
binding domain (residues 1740-1756). (Adapted from (Rosner et al., 2008)
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IV.

Tuberin at the G1/S transition
Aside from the critical regulatory cell cycle proteins, numerous other proteins are

involved in cell cycle control. Tuberin is a known cell cycle regulator at the G1/S and G2/M
transition. Tuberin was first implicated in the regulation of cell cycle control when (Soucek
et al., 1997) found that while both Tuberin protein and mRNA were constantly expressed
throughout the cell cycle, the expression levels were increased in G0 and early G1 cells.
The loss of Tuberin by anti-sense oligonucleotide inhibition resulted in a shortened G1
phase. When depleting Tuberin in quiescent cells, they re-entered the cell cycle and
transitioned into S phase. In serum starved, anti-sense Tuberin inhibited cells, G1/S cell
cycle arrest did not occur. Interestingly, the loss of Tuberin induced an increase in Cyclin
D expression (Soucek et al., 1997). Later studies found that in Drosophila and mammalian
cells, Cyclin D can bind directly to Tuberin independently of CDK4 (Tapon et al., 2001;
Zacharek et al., 2005) and the Cyclin D-Cdk4/6 complex can phosphorylate Tuberin
directly at Ser1217 and Ser1452 inhibiting its activity, thereby, leading to increased protein
synthesis (Romero-Pozuelo et al., 2020). Tuberin possibly acts as a key switch between
senescence and quiescence when cells are arrested in G1 (Maskey et al., 2020)
On the other hand, Tuberin can also negatively regulate the G1/S transition through
its interaction with one of the CKIs, p27, by preventing it from undergoing ubiquitinmediated degradation. In addition to the Tuberin- mediated increase in p27 levels, Tuberin
prevents the 14-3-3- mediated cytoplasmic localization of p27 resulting in its nuclear
accumulation (Rosner et al., 2006, 2007a), further confirming the role of Tuberin in cell
cycle regulation.

13

V.

Tuberin at G2/M Transition
Tuberin also has a role in the cell cycle through regulation of the G2/M checkpoint

(Fidalgo da Silva et al., 2011). Using a Yeast 2 Hybrid (Y2H) screen our lab has
demonstrated that Tuberin can physically bind to Cyclin B1 at the G2/M transition. The
Cyclin B1 region that is responsible for its interaction with Tuberin is the CRS. Using the
CRS as bait, they identified that residues 610 – 941 of Tuberin was sufficient to mediate
binding to both overexpressed and endogenous Cyclin B1. Interestingly, the
phosphorylation status of the CRS in Cyclin B1 also dictated the strength of the TuberinCyclin B1 interaction. Using a phospho-incompetent variant of Cyclin B1, Cyclin B1 5A,
that has been shown to preferentially localize in the cytoplasm, the Tuberin-Cyclin B1
interaction was strengthened (Yang et al., 1998; Hagting et al., 1999; Fidalgo da Silva et
al., 2011). While the fully phosphorylated mimic Cyclin B1 5E, localized in the nucleus
completely after 24 hours, co-expression with Tuberin resulted in 90% of this Cyclin B1
variant remaining in the cytoplasm, the Tuberin-Cyclin B1 binding is decreased.
A recently published paper also showed that the Tuberin-Cyclin B1 interaction is
nutrient sensitive and can directly affect the cell size. By using low nutrient conditions or
an Akt non-phosphorylatable Tuberin mutants (S939A, T1462A), they found that the
binding between Tuberin and Cyclin B1 is decreased when cell are cultured in 0.5% of
serum (Fidalgo da Silva et al., 2011, 2019). At high nutrient conditions, the Tuberin and
Cyclin B1 interaction is increased and the length of G2 is increased. Regulation of cell size
by Tuberin at G1/S and G2/M links these two key cell size checkpoints to ensure the cell
has reached a critical size prior to dividing. Interestingly, CDK1 is also known to
phosphorylate and inhibit the activity of Hamartin as well as interact with Tuberin,
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suggesting that TSC activity is regulated at the G2/M transition (Catania et al., 2001;
Astrinidis et al., 2003). Further research needs to be done to elucidate Tuberin’s function
as a nutrient and growth factor signal integrator and cell cycle regulator at two key cell size
checkpoints.
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Figure 4 Schematic of nutrient regulation of Tuberin on cell cycle progression.
In the presence of nutrients, at G1 phase of the cell cycle, Akt phosphorylates Tuberin and
inhibits its GAP activity. Rheb remains active to activate mTOR resulting in increased
protein synthesis and cell size. At the G2/M transition, Akt phosphorylation of the same
residues increases Tuberin and Cyclin B1 interaction, thereby prolonging G2 phase.
(Fidalgo da Silva et al., 2019). Created with BioRender.com
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VI.

Tuberin’s Role in Tumour Formation
As described above, Tuberin is canonically known to inhibit mTOR, a main driver

of protein synthesis in the cell. When Tuberin or its binding partner, Hamartin are mutated,
it leads to an autosomal dominant tumour disorder known as Tuberous Sclerosis Complex.
Tuberous Sclerosis Complex is characterized by the formation of benign tumours, known
as hamartomas, in multiple organs, such as the skin, eyes, brain, heart, kidney and lungs
(Orlova and Crino, 2010; Rosset et al., 2017). It affects 1 in 6000-10,000 live births
annually from all racial and ethnic backgrounds and is estimated to affect 2 million people
worldwide (Leung and Robson, 2007; Henske et al., 2016). Tuberous Sclerosis Complex
patients have a wide range of phenotypes and severity of the disease. Skin manifestations
are one of the main diagnostic criteria, and approximately 70% of patients usually exhibit
at least one kind of skin feature, the most common being angiofibromas, small nodular
tumours found across the nose and cheeks (McEneaney and Tee, 2019).
The expressivity of the disease varies, but patients with a TSC2 mutation (50% of
individuals) exhibit more severe phenotypes, than TSC1 mutations (20%) (Dabora et al.,
2001a; De Waele et al., 2015). Approximately 60-70% of Tuberous Sclerosis Complex
cases are de novo, because of sporadic germline mutations in either TSC1 or TSC2, while
the remaining cases inherit the disease from their parents in an autosomal dominant fashion
(McEneaney and Tee, 2019).
Mutational studies to understand the phenotypic spectrum of Tuberous Sclerosis
Complex found that TSC1 mutations are commonly nonsense or frame shift mutation that
cause protein truncation. On the other hand, TSC2 mutations vary vastly, with frameshifts,
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missense, nonsense, in-frame deletions and splice mutations causing the disease (Jones et
al., 1999).
Tuberous Sclerosis Complex mutations have led to a better understanding of
Tuberin’s functions. Missense mutations on residues R611, A614, F615, C696, V769 and
Y1571 show decreased binding to Hamartin (Aicher et al., 2001; Nellist, 2001; Astrinidis
et al., 2003). Our lab has further characterized one mutation found in the Cyclin B1 binding
region of Tuberin. Transient transfection in HEK-293 cells with Tuberin-C696Y shows
decreased binding to Cyclin B1 and a higher mitotic index (Fidalgo da Silva et al., 2011).
Lastly, mutations in Tuberin have also been associated with malignant cancers.
Tuberous Sclerosis Complex patients have an increased risk of acquiring renal cell
carcinoma (Rakowski et al., 2006). Other cancers such as medulloblastoma, lung, kidney
and breast cancers have also been shown to be aided by Tuberin mutations by cooperating
with oncogenic mutations (Dabora et al., 2001b; O’Callaghan et al., 2004; Bhatia et al.,
2009; Franz et al., 2010; Orlova and Crino, 2010).
VII. CRISPR/Cas System for Genome Engineering
CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPRassociated protein) is a revolutionary genome editing tool that is more efficient and easily
customizable compared to other existing genome editing technologies. Prior to the
discovery of the CRISPR/Cas, genome editing tools that were used extensively were
protein systems such as meganucleases, zinc-finger nuclease proteins (ZFNs), and
transcription activator like effector nucleases (TALENs). Meganucleases are derived from
naturally occurring restriction enzymes that have been engineered to recognize and cleave
particular DNA sequences of interest (Silva et al., 2011). ZFNs and TALENs are fusion
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proteins that have an engineered DNA binding domain and a nuclease domain derived from
FokI restriction enzyme

(Joung and Sander, 2013; Nemudryi et al., 2014). The

disadvantage to these existing technologies were the high costs and labour associated with
engineering specific protein domains that targeted the gene locus of interest and low
accuracy of DNA cleavage to the region of interest. The more specific method,
CRISPR/Cas uses a guide RNA that directs the Cas endonuclease to the region of interest
in the genome.
CRISPR is the adaptive immunity of bacteria and archaea used to defend against
infection of foreign DNA by phages and conjugative plasmids (Jinek et al., 2012;
Wiedenheft et al., 2012; Barrangou and Marraffini, 2014). When foreign DNA enters the
bacterial cell, short fragments from the foreign DNA sequence are incorporated between
the CRISPR repeats in the CRISPR locus of the bacterial genome. The cell constitutively
transcribes the repeats and processes them into mature CRISPR RNA (crRNA). The
crRNA then forms a duplex with trans-activating CRISPR RNA (tracrRNA) to form a
functional guide RNA (gRNA). Each gRNA binds to and activates the two nuclease
domains of the Cas effector protein. Upon reinfection of the foreign DNA, the gRNA/Cas
complex binds complementarily to the DNA, catalyzes a double stranded break and thereby
inactivates the foreign DNA. Currently, there are two classes of CRISPR/Cas systems, that
are divided into 6 types and then further divided into subtypes (Koonin et al., 2017). The
most used CRISPR/Cas endonuclease for genome engineering is the class 2 type II derived
from Streptococcus pyogenes bacteria.
To simplify the use of CRISPR/Cas for genome engineering, the tracrRNA and
crRNA are fused together to form a 20-nucleotide single-guide RNA (sgRNA). Critical in
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precisely cleaving the targeted gene of interest is the design of the sgRNA, which would
be the first 20 nucleotides that lie 5’ beside the NGG protospacer adjacent motif (PAM)
sequence (Jinek et al., 2012; Ran et al., 2013). After successful recognition of the DNA of
interest in the cell, the Cas protein cleaves the DNA 3 nucleotides 5’ of the PAM sequence.
Following the cleavage of the DNA, the cell’s own DNA damage repair mechanisms act
to repair the cut using one of two methods (Sander and Joung, 2014; Zhang et al., 2016).
The first repair pathway is non-homologous end joining (NHEJ), which quickly joins the
end of the DNA together but introduces indel mutations that can result in premature stop
codons. The second pathway, the homology-directed repair (HDR) pathway, is much less
error-prone but only occurs when the cell is in G2 or mitosis. This pathway is used to insert
the desired mutation and larger fragments of DNA and fluorescent genes for tagging
proteins. When the HDR pathway is used, the gene can be precisely edited through the cotransfection of a homologous guide oligonucleotide with the desired mutation or insert such
as a fluorescent protein tag. Thus, this technology requires the CRISPR vector which
encodes the Cas9 enzyme, a single guide RNA specific to the target sequence. For precise
gene editing, the vector is co-transfected with a guide oligo with the desired mutation. DNA
templates containing genes for fluorescent proteins are co-transfected with guide oligos to
insert these genes into the genome (Koch et al., 2018; Paix et al., 2019).
VIII.

Hypothesis and Objectives

Tuberin’s role at the G2/M transition is still not completely understood. Our lab has
characterized how the Tuberin-Cyclin B1 interaction can regulate entry of mitosis by
spatial regulation of this G2/M cyclin and how the interaction can increase cell size. This
work attempts to address how this complex can be temporally regulated by creating
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phosphomutants of residues in the cytoplasmic retention sequence of Cyclin B1 based on
existing literature available for the CRS phosphorylation sites. Due to the transient nature
of the Tuberin-Cyclin B1interaction, a CRISPR fluorescent tool was developed to better
visualize this interaction at G2/M phase of the cell cycle.
We hypothesize that the Cyclin B1 CRS region's phosphorylation status determines
the formation of the Tuberin-Cyclin B1 complex, and the development of fluorescent
tools will be fundamental in studying this interaction.
Objective 1: Construction of Cyclin B1-GFP CRS variants to determine if Cyclin B1
phosphorylation status increases Tuberin protein levels and alters timing of mitotic
onset. Using mutants of the Tuberin-Cyclin B1 binding regions, the clinical mutant, TSC2
C696Y together with Cyclin B1 CRS variants, to detect changes in protein localization
through immunofluorescent techniques. Use mammalian cell culture to manipulate
amounts of Cyclin B1 to detect changes in Tuberin protein levels via western blotting.
Objective 2: Construction of a human Tuberin iRFP-720 cell line using CRISPR/Cas
technique. Develop a protocol to create Tuberin knock-in iRFP-720 cell line. Assess
knock-in efficiency using fluorescent imaging and flow cytometry analysis.
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MATERIALS AND METHODS
I.

DNA Plasmid Construction

Cyclin B1 CRS variants plasmid construction
The following plasmids were constructed by Dr. Elizabeth Fidalgo da Silva:
pCMV Tag2C Mlu- FLAG (empty control vector)
pCMV Mlu- FLAG-TSC2 WT
The backbone vectors of the full-length human TSC2-Tag2 mammalian expression vectors
(flag-tagged) were generously supplied by J. DeClue.
pCMX Cyclin B1-WT-GFP, pCMX Cyclin B1-5A-GFP, pCMX Cyclin B1-5EGFP vectors were given as a kind gift from Dr. A. Hagting.
pCMX Cyclin B1-4A (A126E)-GFP was constructed by Jessica Dare-Shih.
The following mammalian DNA plasmids were constructed by Jackie Fong
pCMX Cyclin B1-3A (A126E, A128E) -GFP
pCMX Cyclin B1-2A (A126E, A128E, A133E) -GFP
pCMX Cyclin B1-1A (A126E, A128E, A133E, A147E) -GFP
Site-directed mutagenesis was conducted using Invitrogen Platinum SuperFi II DNA
Polymerase (Cat #12361010).
Table 1: Site directed mutagenesis primers for the construction of Cyclin B1
phosphomutants
Vector

Primers (Forward/Reverse)

Cyc B1 3A

(Primer #s C162, C163)
Forward 5' - GATACTGCCGAACCAGAACCAATGGAAACAGCC
Reverse 5' – GGCTGTTTCCATTGGTTCTGGTTCGGCAGTATC
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CyclinB1- 2A (Primer #s C442, C443)
Forward 5' CCGAACCAGCCCCCATGGAAACAGAAGGATGCGCACCTGCA
GAAGAAGACC
Reverse 5' GCAGGTGCGCATCCTTCTGTTTCCATGGGGGCTGGTTCGGCA
GTATCAACC
Cyclin B1 1A (Primer #s C444, C445)
Forward 5'
GAAGACCTGTGCCAGGCCTTCGAAGATGTAATTCTTGTAGTA
AATG
Reverse 5'
CTACAAGAATTACATCTTCGAAGGCCTGGCACAGGTCTTCTT
CTGC
CRISPR iRFP-720 Knock-In
The following iRFP 720 CRISPR vectors were constructed by Jackie Fong
piRFP 720-N1-TSC2 Template (hereafter TSC2 iRFP 720 Vector 1)
piRFP 720-N1-TSC2 Template (hereafter TSC2 iRFP 720 Vector 2)
piRFP 720-N1 del stop
piRFP 720-N1 del stop-TSC2 Template (hereafter TSC2 iRFP 720 Vector 3)
PX459 sgRNA TSC2.iRFP 720 Guide 1
PX459 sgRNA TSC2.iRFP 720 Guide 2
PX459 sgRNA iRFP 720.TSC2 Guide 1
PX459 sgRNA iRFP 720.TSC2 Guide 2
piRFP720-N1 was a gift from Vladislav Verkhusha (Addgene plasmid # 45461;
http://n2t.net/addgene:45461 ; RRID:Addgene_45461)
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pSpCas9(BB)-2A-Puro (PX459) V2.0 was a gift from Feng Zhang (Addgene plasmid #
62988 ; http://n2t.net/addgene:62988 ; RRID:Addgene_62988)
The template vectors (TSC2 iRFP 720 Vector 1 – 3) were constructed using
standard molecular cloning techniques. The homologue arms were amplified from HEK293 genomic DNA extracted using a genomic DNA miniprep kit (Biobasic; Cat# BS88503)
and primers used for the amplification are found in Table 2. After amplification, the PCR
products underwent restriction digestion with the respective restriction enzymes, and were
then gel extracted. Ligation of the backbone vector and homologue arms were conducted
using Thermo Scientific T4 DNA Ligase (Cat # EL0011).
CRISPOR.org was used to find gRNAs with low off-target and high on-target
predictions (Concordet and Haeussler, 2018). Approximately 170 nucleotides 5’ of the start
codon and 5’ of the stop codon of human TSC2 was inputted into the sequence box,
selecting Homo sapiens as the genome, and “20bp-NGG – Sp Cas9, SpCas9-HF1, eSPCas9
1.1” as the Protospacer Adjacent Motif (PAM). The guide sequence that provided the
highest specificity score and closest to the start or stop codon was chosen.
The oligos for the guide sequences were synthesized by Eurofins. The forward
and reverse oligos were phosphorylated and annealed simultaneously. The annealed oligos
were digested and ligated with the px459 backbone vector to create the various PX459
sgRNA plasmids above.
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Table 2 Primers used to construct the CRISPR templates for the creation of TSC2 iRFP
720 cell lines
Vector/DNA
Sequence

Primers

piRFP 720-

(Primer #s C553, C554)

N1 del stop

Forward - 5' GATCGGCGTGATGGAGGAGAAGCGGCCGCG

codon

Reverse - 5' CGCGGCCGCTTCTCCTCCATCACGCCGATC

PX459

Guide 1 (Primer #s C564, C565)

sgRNA iRFP

Forward - 5' CACCgAGGGGTTTTCTGGTGCGTCCTGG

720. TSC2

Reverse - 5' AAACCCAGGACGCACCAGAAAACCCCTc
Guide 2 (Primer #s C725, C726)
Forward - 5' CACCgAGGGGTTTTCTGGTGCGTCC
Reverse - 5' AAACGGACGCACCAGAAAACCCCTc

PX459

Guide 1 (Primer #s C566, C567)

sgRNATSC2

Forward - 5' CACCgGCGCCTCATCTCCTCGGTGGAGG

.iRFP 720

Reverse - 5' AAACCCTCCACCGAGGAGATGAGGCGCc
Guide 2 (Primer #s C727, C728)
Forward - 5' CACCGCGCCTCATCTCCTCGGTGG
Reverse - 5' AAACCCACCGAGGAGATGAGGCGC

TSC2.iRFP
720 Vector 1

5’ Homologue Arm (Primer #s C700, C701)
Forward - 5'
aaatttgAATTCGCGCCCAGATGTGGAGGGGGCTTGGCCTGG
Reverse - 5'
aaatttCCGGTGCTTCCTCCGCTTGTTCCTCCCACAAACTCGG
TGAAGTCC
3’ Homologue Arm (Primer #s C702, C703)
Forward - 5'
aaatttGGCCGCCTCCCTCCTGCACTGGCCTTGGACGGTATTG
C
Reverse - 5'
aaatttAATTGCCTTGGGAAGGACACAGCAGTATTGGACGG
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TSC2.iRFP
720 Vector 2

5’ Homologue Arm ((Primer #s C753, C754)
Forward 5’ –
aaatttGAATTCGCGCCTCATCTCCTCGGTGGAGGCCATGG
AGCTGACAGGTGTCTA
Reverse 5’ aaatttACCGGTACCTCCGCTACCTCCACCACTACCTCCCC
GAGGAGATGAGGCGCT
3’ Homologue Arm (Primer #s C755, C756)
Forward 5’aaatttGCGGCCGCTGGAGGACTTCACCGAGTTTGT
Reverse 5’ aaatttGTTAACCCTCCACCGAGGAGATGAGGCGCATTTCC
CCGAGTCCTCAGGTAC

iRFP

5’ Homologue Arm (Primer #s C757, C758)

720.TSC2

Forward 5’-

Vector 3

aaatttGAATTCAGGGGTTTTCTGGTGCGTCCTGGGACTCC
TGCGGACTACACATCC
Reverse 5’- aaatttACCGGTCGCACCAGAAAACCCCTCTG
3’ Homologue Arm (Primer #s C759, C760)
Forward 5’ –
aaatttGCGGCCGCGGAGGTAGTGGTGGAGGTAGCGGAGG
TTCCTGGTCCACCATGGCC
Reverse 5’ aaatttGAATTGCCAGGACGCACCAGAAAACCCCTATCAC
CTGAGGTCAGCAGTTCA
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II.

Antibodies

The following antibodies were used in western blotting, co-immunoprecipitation, and
immunofluorescence analysis:
Mouse α-Cyclin B1 (monoclonal; Santa Cruz; Cat#: sc-245)
Mouse α-Cyclin B1(monoclonal; Thermo; Cat#: MA5-14319)
Mouse α-actin (monoclonal; Millipore; Cat# MAB1501)
Rabbit α-Hamartin (monoclonal; Cell Signaling; Cat #4906)
Rabbit α-Tuberin (polyclonal; Santa Cruz; Cat # sc-893)
Mouse α-FLAG (monoclonal; Sigma; Cat# F1804)
III.

Mammalian Cell Culture
HEK-293 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM)

supplemented with 10% Fetal Bovine Serum (FBS; Thermo-Fisher; Lot#906532) and 1%
Penicillin-Streptomycin (Gibco; Cat#15140122). They were incubated at 37˚C in 5% CO2.
For serum starvation, cells were cultured in DMEM supplemented with 1% PenicillinStreptomycin and incubated for 16 hours. For treatment with HDR Enhancer (IDT; Cat
#1081072), a final concentration of 30 µM and removed 24 hours after.
IV.

Double Thymidine Block
HEK-293 cells were transfected as described above after 24 hours of incubation

with the transfection reagent. Cells were washed with 1 mL of 1xPBS and replaced with
fresh supplemented DMEM. Cells recovered for 8 hours and were then incubated with 2
mM of thymidine (Sigma) for 18 hours at 37˚C in 5% CO2. After thymidine incubation,
they were washed with 1xPBS, allowed to recover for 8 hours and the 2mM thymidine
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block was repeated overnight, followed by a wash with 1xPBS to release the cells from Sphase arrest.
V.

Protein overexpression and Concentration Determination
Cells were seeded the day before transfection and were transfected when they

reached 70% confluency. For a 70% confluent 10-cm tissue culture dish, the transfection
mixture was prepared with 500 µL of full media, 10 µg of DNA and 30 µg of 1 mg/ml
branched polyethyleneimine reagent (PEI, Sigma; Cat# 408719). Upon the addition of PEI,
the mixture was immediately vortexed for 12 seconds and incubated at room temperature
for 10 minutes. After incubation, the transfection mixture was added to the cells dropwise.
Transfected cells were incubated for 24 hours at 37˚C in 5% CO2. Before
collection, successful transfection was verified by fluorescence microscopy if a fluorescent
reporter was transfected. The transfected cells were collected by pipetting, spun at 1000
rpm for 5 min at 4˚C, washed once with 1xPBS, and either froze immediately at
-80˚C or lysed. Depending on the specific application, cells were lysed with either TNE
(50 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 1% Triton) or IP LB (20 mM Tris pH
8.0, 137 mM NaCl, 100 mM Glycerol, 10 mM NP40, 2 mM EDTA). The volume of lysis
buffer depended on the size of the pellet and varied from 150 µL to 500 µL. Cells were
incubated for 30 minutes on ice then centrifuged at 10000 rpm for 10 min at 4˚C. The cell
debris pellet was removed from the lysate with a sterile pipette tip.
The samples' protein concentrations were determined using the Bradford Assay.
Briefly, 995 µL of Bradford reagent was quickly vortexed with 5 µL of lysate in a 1.5 mL
Eppendorf tube. The standard curve was made just prior to the measurement of the samples
and needed a regression of 0.960 or higher before proceeding.
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VI.

Co-immunoprecipitation (Co-IP)
Transfected cells were collected and lysed as previously described. 5 µL of

primary antibody was added to either 500 µg or 1000 µg of lysate and the volume was
completed to 500 µL with 1xLB with protease inhibitors. The samples were rotated
overnight at 4ºC. The next day, 5 µL of Protein G Sepharose beads (Sigma) were added to
each sample and rotated for 3 hours at 4ºC. Following incubation, the samples were
centrifuged at 2000 rpm for 2 min at 4ºC, 400 µL of supernatant was aspirated, replaced
with fresh 1xLB, and manually inverted once. This was repeated 2 more times to wash
away non-specific protein interactions. After the final spin, all but 75 µL of supernatant
was aspirated, 4x sample buffer was added to the sample to complete the volume to 100
µL. Samples were immediately vortexed and heated for 5 minutes at 95ºC then stored in 20ºC until they were run on a SDS-PAGE gel and western blotting.
VII.

Western Blotting
After protein sample denaturation, samples were run on a 10% SDS-PAGE

(sodium dodecyl sulfate-polyacrylamide gel) at 120 V for 2.5 – 3 hours. The protein was
then transferred onto a 0.45 µm polyvinyidene fluoride (PVDF) membrane (Millipore;
Cat# IPVH00010) at 30 V for 2.5 hours. Following the transfer, the PVDF membrane was
blocked with 1% milk in Tris-buffered saline with 10% Tween-20 (TBST) for 1 hour at
room temperature. The blocked membrane was then incubated with a primary antibody in
1% milk at 1:1000 overnight at 4˚C on a rotator. The membrane was washed in TBST 3
times for 10 minutes, and then incubated with the secondary antibody in 1% milk at
1:10000 dilution for 1 hour at room temperature on a rotator. Subsequently, the membrane
was washed with TBST for 5 minutes, a total of three times. Chemiluminescence of the
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protein was triggered by the addition of equal amounts of ECL (enhanced
chemiluminescent substrate) and 0.01% H2O2 reagents (Thermo-Fisher; Cat#32106) and
imaged using the AlphaInnotech equipment. The resultant protein bands were quantified
with ImageJ as described in (Davarinejad).
VIII.

Immunofluorescence (IF)
HEK-293 cells were seeded onto sterile coverslips in 10-cm cell culture dishes

with 7 mL of full media. Cells were grown to approximately 70% confluency and
transfected with 10 µg of DNA. After 24 hours of incubation at 37oC in 5% CO2, cells and
coverslips were collected. Coverslips were fixed with 4% formaldehyde for 15 minutes at
room temperature and then immersed in a 50% glycerol: 50% PBS solution and stored at 20ºC. For preparation of immunofluorescence staining, coverslips were washed with 100
µL of 1xPBS for 5 minutes a total of three times and then permeabilized with 100 µL of
0.2% Triton X-100 for 10 minutes. The slips were then blocked with 100 µL of LAP
Blocker for 30 minutes and incubated with 100 µL of primary antibody (1:500 in 1xPBS)
for 1 hour. Again, coverslips were washed 3 times for 5 minutes with 100 µL of 1xPBS.
Next, 100 µL of secondary antibody (1:1000 in 1xPBS) was added for 30 minutes. The
nucleus was stained with 10 minutes of Hoechst. Lastly, the slips were washed for 5
minutes with 1xPBS, a total of three times. Slips were mounted onto the slide using 2 µL
of mounting solution and left for 24 hours. Coverslips were fixed onto the slide with Revlon
clear nail polish. Cell images were obtained using LAS AF6000 software with a LEICA
DMI6000 fluorescent microscope (Wetzlar, Germany).
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IX.

Quantification of Immunofluorescent Protein Localization and
percentage of mitotic cells
Immunofluorescent images were taken under equal exposure times and saved as

numbered .tiff files. Numbered images were analyzed by an unbiased researcher. Images
of protein localization were counted as cytoplasmic if protein was observed as very spread
out and elongated within the cell, whether it was free in the cytosol (diffuse), or organelle
bound (punctate). Cells were counted as nuclear localization when the protein was
concentrated within the nucleus, through observation of a significant overlap with the
DAPI channel.
Phospho-histone 3 was used to determine the percentage of mitotic cells. ImageJ
was used to analyse the number of cells in an image. This was done by using the DAPI
channel images, converting the image to an 8-bit image, changing the threshold of the
image to convert it to a black and white image and then using the “Analyze Particles”
function to automatically count the number of cells. For cell clusters that were
automatically counted as one cell, they were manually counted by hand. Phospho-histone
3 staining was manually counted, with cells that have condensed chromosomes counted as
2 cells.
X.

Protein Sequence Alignment Analysis
Homologs of human Cyclin B1 (P14635) from Drosophila melanogaster

(P20439), Danio rerio (Q7ZU21), Xenopus laevis (P13350), and Mus musculus (P24860)
were aligned using Clustal Omega Multiple Sequence Alignment program set with default
parameters. (https://www.ebi.ac.uk/Tools/msa/clustalo/) (Goujon et al., 2010; Sievers et
al., 2011)
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XI.

Flow Cytometry and Cell Cycle Profile Analysis
Cells were cultured, treated, and collected as described previously. Following

centrifugation, cells were fixed with ice cold 70% ethanol, and pipetted gently to resuspend the pellet. They were then stored at -20 oC for a minimum of 30 minutes to prepare
for cell cycle profile analysis. Fixed cells were washed with 1 mL of 1xPBS with 0.05 mM
of filter-sterilized EDTA twice for 5 minutes at 1000 rpm at 4oC. Cells were then
resuspended in 500 µL of the washing solution (0.05 mM EDTA in 1xPBS) and 25µL of
250µg/mL of propidium iodide was added. Using the BD Biosciences LSR Fortessa X-20
Cell Analyzer, cell cycle profiles were measured based on DNA content.
For the CRISPR iRFP 720 cells, fluorescent tag insertion efficiency was
determined by the BD Biosciences LSR Fortessa X-20 Cell Analyzer using the red laser
and 730/45 filter. To isolate the CRISPR iRFP 720 positive population (HEK293 JF), live
cells were washed three times with 1XPBS and resuspended in 500μL of 1XPBS. Cells
were filtered through a 70 μm cell strainer and were sorted by fluorescence-activated cell
sorting (FACS) using the BD FACSAria FusionTM 5-Laser 18-Colour with ACDU utilizing
the 760/45 nm filters. HEK-293 cells were used for FACS to calibrate cell size and to gate
for the negative fluorescence population. HEK-293 cells transiently transfected with
piRFP-720-N1 was used to gate for the positive fluorescence population.
XII.

Statistical Analysis
A linear regression was performed on Tuberin protein levels with graded

amounts of Cyclin B1 5A using Microsoft Excel’s Analysis ToolPak.
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Poisson model specification
A Poisson regression model was chosen to analyze the significance of the
percentage of mitotic cells between the Cyclin B1 CRS variants (Figure 10). As the
outcome of interest was the proportion based on the count of mitotic cells among a
population of cells, this statistical model takes into account the varying cell population. For
the regression, the outcome variable was the average number of mitotic cells, adjusted for
the predictors (presence of wildtype tuberin and Cyclin B1 CRS variant) and cell
population. The predictors can be treated as binary indicator variables (a value of 1
indicates its presence and 0 indicates not present). Also, the variables for the Cyclin B1
variant (5A to 5E) are mutually exclusive (i.e. the presence of one type of mutation
indicates the absence of the other mutations). If the test-statistic associated with the
regression coefficients had a p < 0.05, the regression term was deemed statistically
significant (it has an impact on the percent of mitotic cells after adjusting for the other
terms).
Post-hoc analysis (multiple group comparisons):
To see if the percentage of mitotic cells differ among the various Cyclin B1 variants, a
post-hoc analysis was performed on the model results using Tukey's honest significance
test (HSD). Comparisons with a p-value for a test-statistic that was < 0.05 were deemed to
be significantly different.
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Interpreting regression coefficients in log form. (Appendix 4):
The *intercept* is the log percentage of cells that are mitotic in the mock group with no
Tuberin WT. *β1* is the log ratio of percentage of cells that are mitotic in the cells with
Tuberin WT compared to cells with no Tuberin WT (after adjusting for the presence of
cyclin mutations). *β2* is the log ratio of the percentage of cells that are mitotic in the
cells with the Cyclin 5A mutation compared to mock (after adjusting for the presence of
Tuberin WT) and so forth.
Interpreting exponentiated regression coefficients:
*exp(intercept)* is the percent of cells that are mitotic in the mock group with no Tuberin
WT (after adjustment for presence of cyclin mutations). *exp(β1)* is the ratio of percentage
of cells that are mitotic in the cells with Tuberin WT compared to cells with no Tuberin
WT (after adjustment for presence of cyclin mutations). *exp(β2)* is the ratio of the
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percentage of cells that are mitotic in the cells with the Cyclin 5A mutation compared to
mock (after adjustment for presence of cyclin mutations) and so forth.
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RESULTS
I.

Tuberin-Cyclin B1 interaction affects Tuberin cellular localization and
protein levels.
Tuberin controls mitotic onset by forming a complex with the mitotic cyclin,

Cyclin B1, and localizing this cyclin in the cytoplasm, preventing its entry into the nucleus
(Fidalgo da Silva et al., 2011) . Previously unpublished work from our lab has suggested
that abrogation of Tuberin and Cyclin B1 binding decreases protein levels of Tuberin. A
previously characterized and clinically relevant mutant of Tuberin, TSC2-C696Y, has been
shown to have reduced binding to Cyclin B1 (Fidalgo da Silva et al., 2011). To determine
if the Tuberin-Cyclin B1 binding may influence Tuberin localization, we co-transfected
HEK-293 cells with Cyclin B1-GFP and a previously characterized and clinically relevant
mutant of Tuberin, Tuberin-C696Y. This mutant protein binds less Cyclin B1 than Tuberin
WT (Fidalgo da Silva et al., 2011). Immunocytochemistry with Tuberin antibody and
Hoechst nuclear counterstain demonstrated specific co-transfection-dependent differences
in the presence of Tuberin fluorescent signal between cytoplasm and nucleus (Figure 5A).
The ImageJ analysis and quantification, revealed that the C696Y mutant of Tuberin
presents significantly upregulated nuclear protein localization (p < 0.05), when compared
to Tuberin WT which was found to be primarily cytoplasmic (Figure 5B).
To determine if Tuberin protein levels are altered in the presence of Cyclin B1
overexpression, equal amounts of TSC2 WT DNA was co-transfected in HEK-293 cells
with increasing DNA amounts of Cyclin B1 5A, a Cyclin B1 mutant of enhanced binding
properties to Tuberin (Fidalgo da Silva et al., 2011). Western blot technique was used to
assess Tuberin protein levels (Figure 6A), quantified by densitometry. Linear regression
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showed there was no significant correlation between the amount of Cyclin B1 5A
transfected and Tuberin protein levels (Figure 6B).
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Figure 5: Clinical mutant Tuberin-C696Y exhibits higher nuclear localization than
Tuberin WT.
HEK-293 cells were transfected with either Cyclin B1-GFP (CycB1), Tuberin WT, Tuberin
C696Y, or combinations of Cyclin B1 and Tuberin constructs. (A) Immunofluorescence
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images depicting nuclei (blue), Tuberin over-expression (red), and Cyclin B1 WT protein
(green) at 100x objective. (B) Graph depicting cytoplasmic localization (black bars) vs.
nuclear localization (white bars) of Tuberin protein (when co-expressed with Cyclin B1)
as a percentage of total number of cells overexpressing both Tuberin and Cyclin B1.
* p<0.05. Statistical significance was assessed using student’s unpaired t-test.
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Figure 6: Graded amounts of mutant Cyclin B1 5A does not lead to altered Tuberin
protein levels.
HEK-293 cells were co-transfected with equal amounts of FLAG-Tuberin WT and
varying amounts of mock or Cyclin B1 5A for a total of 10 µg of DNA. (A)
Representative western blot depicting immunoblot of FLAG (top panel), Cyclin B1
(CycB1, middle panel) and Actin as the loading control (bottom panel). (B) Level of
FLAG-Tuberin over-expression was measured using densitometry. Statistical analysis
was conducted using linear regression of Tuberin protein level vs. amount of Cyclin B1
5A transfected (R2= 0.0859; p=0.16453).
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A panel of Cyclin B1 CRS variants was created to further dissect each of the serine
residues' essentiality in the formation of the Tuberin/Cyclin B1 complex. Understanding
the conservation of these residues between species can shed some light on each of these
residues' importance for our studies. The sequences of Cyclin B1 from Drosophila
melanogaster, Danio rerio, Xenopus laevis, human, and Mus musculus were aligned using
Clustal Omega multiple sequence alignment program (Figure 7). Of the residues, only S126
and S147 exhibited perfect alignment, and S133 showed weak alignment. In comparison,
S128 was conserved in Xenopus laevis, Mus musculus, and humans. This residue is
replaced with valine in Drosophila melanogaster and Danio rerio. S116 was only
conserved in Mus musculus, and the corresponding aligned amino acid in Drosophila
melanogaster, Danio rerio, Xenopus laevis are threonine, histidine, and cysteine,
respectively. Overall, it seems that these residues play an important role in the CRS
domain.
The existing Cyclin B1 CRS variants were sequentially mutated from Cyclin B1
5A to construct the corresponding mutants in the following order: Cyclin B1 4A with
alanine (A) 126 residue mutated to a glutamic acid residue (E); Cyclin B1 3A with A128
residue mutated to an E; Cyclin B1 2A with A133 residue mutated to an E; and lastly Cyclin
B1 1A with A147 residue mutated to an E (Figure 8A). Plasmids 3A, 2A, and 1A were
created for this thesis, and the corresponding plasmid maps also show the mutations and
silent sites that were introduced for clone screening purposes (Figure 8B). For Cyclin B1
3A, clones were digested with HindIII to ensure it is the proper size before clones were
sent for DNA sequencing (Figure 8C; top panel). A NcoI silent site was introduced into
Cyclin B1 2A for screening purposes, successful clones when digested with NcoI resulted
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in 5 bands in the agarose gel at 2.8 kB, 1.8 kB, 1.1 kB, 0.4 kB, and 0.3 kB (Figure 8C;
middle panel). While a Bsp119I silent site was introduced to screen for successful Cyclin
B1 1A clones, which would result in 2 bands on the agarose gel at 4.9 kB and 1.5 kB
(Figure 8C; bottom panel). All Cyclin B1 CRS variants were co-transfected into HEK-293
cells with Tuberin WT to determine successful expression of the plasmids (Figure 8D).
Densitometry analysis was also done to compare the protein levels of Tuberin when cotransfected with the various Cyclin B1 CRS variants. Tuberin protein levels from the Mock
and Tuberin were set to 1 and the Cyclin B1 CRS variants samples were determined by
fold change. When comparing the levels between each other, it was not statistically
significant (p>0.05) (Figure 8E).
Co-immunoprecipitation experiment was performed to determine the binding
affinity of Tuberin to the Cyclin B1 CRS variants, 5A, 4A, 3A, 1A, and 5E. Successful
over-expression of the plasmids are shown in Figure 9A. The co-immunoprecipitation blot
using Cyclin B1 is shown in Figure 9B. Quantification of the co-immunoprecipitation blot
shows a decreasing amount of FLAG-Tuberin bound to Cyclin B1 as the phosphorylation
status of the CRS increased, with the exception of 1A which had a comparable amount of
Tuberin bound as 5A but this is only one trial (Figure 9C).
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116

126128 133

147

Figure 7: Alignment of the Cytoplasmic Retention Sequence in Cyclin B1.
The protein sequence alignment was generated using Clustal Omega multiple sequence
alignment program (version 1.2.4) The cytoplasmic retention sequence of Drosophila
melanogaster (sp | P20439 | CCNB_DROME), Danio rerio (tr | Q7ZU21 |
Q7ZU21_DANRE), Xenopus laevis (sp | P13350 | CCNB_XENLA), human (sp | P14635 |
CCNB_HUMAN), Mus musculus (sp | P24860 | CCNB_MOUSE) were aligned.
Phosphorylation sites of the human cytoplasmic retention sequence in Cyclin B1 are
indicated by the black boxes and labelled. “*” indicates perfect alignment. “:” indicates a
site belonging to group exhibiting strong similarity. “.” indicates a site belonging to a group
exhibiting weak similarity.
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Figure 8: Construction and analysis of the Cyclin B1 CRS variants.
Mutant variants were created to assess the binding of Cyclin B1 to Tuberin by performing
site-directed mutagenesis on the 5 key serine residues in the cytoplasmic retention
sequence. (A) A schematic of the residues that are mutated for each variant. (B) Vector
maps of the Cyclin B1 (CycB1) protein variants that were constructed. For the screening
of clones, a NcoI silent site was introduced to Cyclin B1 2A and a Bsp119I silent site was
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introduced in Cyclin B1 1A. (C) Corresponding agarose gel images of successful SDM
clones. (D) Western blot of successful transient transfection and expression of Cyclin B1
CRS variant (Cyc B1) plasmids and WT FLAG-Tuberin (Tuberin) in HEK-293 cells. (E)
Densitometry analysis of Tuberin protein levels relative to Actin (fold change) p>0.05.
Statistical significance assessed using Student’s unpaired t-test.
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Figure 9: Phosphorylation of CDK1 residues on Cyclin B1 CRS leads to decreased
binding to Tuberin.
HEK-293 cells were transfected with empty control vector (mock), FLAG-Tuberin WT
and the indicated Cyclin B1 CRS variants. (A) Western blot confirming successful overexpression of the vectors. Actin was used as the loading control. (B) Coimmunoprecipitation blot of Cyclin B1 precipitated protein and co-immunoprecipitated
FLAG-Tuberin protein. (C) Graph of the amount of FLAG-Tuberin bound to Cyclin B1 as
a ratio of the densitometry of the protein bands.
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II.

Determining how the phosphorylation of the CRS region affects mitotic
onset
To determine how the phosphorylation status of the CRS may change the onset of

mitosis, immunofluorescent techniques were used to stain for phospho-Histone 3 (pH3) to
assess the mitotic index. HEK-293 cells were co-transfected with Tuberin WT and each of
the CRS variants (Figure 10A). pH3 stained cells were counted and graphed as a percent
of mitotic cells over total cells counted (Figure 10B). The results indicate that Cyclin B1
5E and Cyclin B1 1A had significantly more mitotic cells than compared to the Mock,
Mock and Tuberin WT, Cyclin B1 3A and Tuberin WT, and Cyclin B1 2A and Tuberin
WT (p< 0.05). Cyclin B1 4A also had significantly more mitotic cells than when Tuberin
was co-transfected with Mock or Cyclin B1 3A. The only difference between Cyclin B1
5E and Cyclin B1 1A is the status of phosphorylation of S116, where has glutamic acid or
alanine residues at that position, respectively. Combining the results of this experiment and
the alignment sequence of the CRS region (Figure 7), we conclude that the phosphorylation
of this residue is not essential for the nuclear translocation of Cyclin B1 to the nucleus.
Further, to determine whether the phosphorylation status of the Cyclin B1 CRS
affects the timing to mitotic onset, 24 hours post-transfection with Cyclin B1 5A, 4A, 3A,
and 5E, HEK-293 cells were subjected to a double thymidine block and collected at 0, 4, 6
and 8 hours (Figure 10C). 1000 cells were counted to determine the percentage of cells
expressing pH3, a marker for mitotic cells (Hans and Dimitrov, 2001). By 8 hours, 85%
of the cells transfected with Cyclin B1 5E and Tuberin were in mitosis; however, Cyclin
B1 5A, 4A, and 3A all had less than 20% of the cells in mitosis and had remained at the
same levels throughout the time course. By 8 hours, 85% of the cells transfected with
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Cyclin B1 5E and Tuberin were in mitosis. However, Cyclin B1 5A, 4A, and 3A all had
less than 20% of the cells in mitosis and had remained at the same levels throughout the
time course. These results confirm our hypothesis that the phosphorylation of residues in
the Cyclin CRS region plays an important role in the Tuberin retention of Cyclin in the
cytoplasm delaying the mitotic onset.
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Figure 10: Cyclin B1 1A and 5E have significantly more mitotic cells than other Cyclin
B1 CRS variants.
HEK-293 cells were seeded on coverslips and transiently transfected with pCMV empty
control (Mock), FLAG TSC2 WT, and the indicated Cyclin B1 CRS variants vectors.
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Coverslips were collected 24 hours post-transfection and stained with DAPI and phosphoHistone 3 (pH3) antibody. (A) Immunofluorescence images depicting nuclei (blue), Cyclin
B1 WT protein (green), and pH3 (red) at 20x magnification. (B) Graph depicting the
percentage of mitotic cells in each condition determined by the number of pH3 stained
cells. * p<0.05. Statistical significance was assessed by Poisson regression. (C) 24 hours
post-transfection with the indicated Cyclin B1 CRS variants and FLAG TSC2 WT, HEK293 cells were subjected to a double thymidine block, released and collected at 0, 4, 6 and
8 hours. 1000 cells were counted to determine the percentage of cells expressing pH3.
Mitotic activity of CRS variants measured as a function of % pH3 expressing cells.
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III.

Developing a HEK293 Tuberin Knock-in iRFP 720 Cell Line
(HEK293JF)
Tuberin is a large protein containing 1807 amino acids, and the full tertiary

structure has not been elucidated. To better understand Tuberin interactions with its
partners, it is of great importance to develop tools for imaging and flow cytometry studies.
Thus, a Tuberin amino and carboxy fluorescent protein gene knock-in with a flexible linker
were designed (Roberts et al., 2017). The main Tuberin protein complex of interest in our
lab is the Tuberin-Cyclin B1 complex at G2/M cell cycle transition. Previously, fluorescent
tools developed used a GFP tag on Cyclin B1 and a CFP tag with a G2/M reporter (Fidalgo
da Silva et al., 2016). Consideration was also given to the visualization of other complexes
of interest that would allow further dissection of this protein-protein interaction with the
existing capabilities of the fluorescent microscope available for imaging. Thus, a nearinfrared fluorescent protein (iRFP 720) tag was chosen (Shcherbakova and Verkhusha,
2013) to be inserted into the genome tagging Tuberin.
The genomic regions that surround TSC2 are shown in Figure 11A. The gRNA
for the N-terminus and C-terminus was designed using http://crispor.tefor.net/ (Concordet
and Haeussler, 2018). For the N-terminus, the guide sequence with the highest specificity
score, 90%, was chosen while for the C-terminus, the guide sequence chosen had a
specificity score of 80% (Figure 11B). The gRNA oligos were annealed and inserted into
the PX459 at the BbsI site (Figure 11C) using T4 DNA ligase. The PX459 plasmid contains
the Cas9 gene for the expression of the Cas9 enzyme that will cut the genomic DNA at the
position determined by the guide RNA (Figure 11). Donor templates were designed
considering the optimization suggested by Zhang et al. and Song & Stieger (Song and
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Stieger, 2017; Zhang et al., 2017), as the length and insertion method may play an essential
role in the frequency of HDR. The templates used in this thesis have the size between 0.8
and 0.9 kb. They were extracted from the genome DNA of HEK-293 cells by PCR and
cloned into the piRFP-720 plasmid using T4-ligase. (Figure 12 and 13).
The guides and donor vector with the homologue arms were transfected into HEK293 cells using diverse conditions, described by Koch (Koch et al., 2018). We used flow
cytometry to screen for positive clones of cells containing the iRFP 720 tag inserted into
the genomic DNA of HEK-293 cells (Figure 16). The positive clones were named HEK293 JF cell lines. The efficiency of iRFP 720 insertion into the genome was dependent on
a few conditions (Figure 16C) and varies between 0.2 to 7.5%. The best efficiency was
obtained with Vector 2 Guide 1 using serum starvation and equal amounts of gRNA
plasmid and donor template plasmid.
Cell populations were sorted based on iRFP 720 positive and negative
fluorescence to enrich the iRFP 720 positive population and grown until there were enough
cells for a confluent 10-cm plate to single-cell sort. A representative flow cytometry plot
of the single-cell sort is shown in Figure 17A. The table (Figure 17B) shows the percent
iRFP 720 positive cells that were present at the time of the single-cell sort. The iRFP 720
positive population ranged from 0.6% to 4.3%. One 96- well plate was filled up with sorted
cells for each condition. From each one 96-well plates that were sorted, many of the singlecell clones were not viable. The viable clones only arose from HEK-293 cells that were
transfected with Vector 3 (amino-terminus iRFP 720 insertion). Based on this result, more
cells will need to be single-cell sorted to screen more clones.
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Immunofluorescent techniques were used to compare the co-localization of
Tuberin (green) and the expression of iRFP 720 (red) in a viable clone (Figure 17C). The
images show that the iRFP 720 fluorescence co-localizes with the Alexa 488 fluorescence
staining for Tuberin. This indicates that the iRFP 720 protein is indeed tagging Tuberin
and is not a possible off-target event.
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5’ AGGGGTTTTCTGGTGCGTCC TGG
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Figure 11: Design of gRNA and creation of CRISPR/Cas PX459 sgRNA plasmids.
(A) Genome regions that surround human TSC2. (B) Depiction of guide sequence output
from CRISPOR.org for the N-terminal insertion of iRFP 720 tag (top) and the C-terminal
insertion of the iRFP 720 tag (bottom). The chosen PAM site is boxed in red. The start and
stop codon are highlighted in yellow. (C) The PX459 plasmid with the guide RNA
sequence from Panel B will be inserted at the BbsI restriction sites indicated.
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Figure 12: Design of CRISPR donor template.
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(A) Target locus of the N-terminus and C-terminus insertion of iRFP 720. Green arrows
are the guide sequences used. The region where CRISPR/Cas will create the doublestranded break is indicated by the end of the green arrow. The purple boxes represent the
3’ Homology Arm Forward Primer used to amplify the 3’ Homology Arm and the 5’
Homology Arm Reverse Primer used to amplify the 5’ Homology Arm. The schematic was
generated using SnapGene Viewer, version 5.1.5, from GSL Biotech; available at
snapgene.com (B) Schematic of iRFP 720 tag insertion and restriction sites used for
digestion and ligation of homology arms to the donor template, in the genome at the Nterminus and C-terminus of TSC2.
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Figure 13: Construction of CRISPR donor template vector 1.
Cloning process of donor template vectors. (A) Schematic of cloning process for donor
template vectors. (B) Plasmid maps of 5’ homologue arm vector and the final donor
60

template vector. Restriction sites used to ligate homologue arms are shown on the
plasmid. The plasmid maps were generated using SnapGene Viewer, version 5.1.5, from
GSL Biotech; available at snapgene.com. (C) Corresponding agarose gel images
depicting successful ligation of homologue arms into parent vector.
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Figure 14: Construction of donor template vector 2.
(A) TSC2 iRFP 720 Vector 2 Plasmid maps of the ligation of the 5’ and 3’ homologue
arm into parent vector. The restriction sites used for ligation are indicated. The plasmid
map was generated using SnapGene Viewer, version 5.1.5, from GSL Biotech; available
at snapgene.com. (B) Corresponding gel images to screen for clones with successful
ligation of homologue arms into parent vector.
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Figure 15: Construction of donor template vector 3.
(A) Using site-directed mutagenesis, a piRFP 720 N1 del stop was created to generate an
N-terminus iRFP tag on Tuberin. A BseRI silent site was introduced for screening
purposes. (B) Plasmid maps of the stepwise construction of the template vector, with
restriction sites used for ligation indicated. The plasmid map was generated using
SnapGene Viewer, version 5.1.5, from GSL Biotech; available at snapgene.com) (C)
Corresponding gel images to screen for clones with successful ligation of homologue
arms into parent vector.
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Figure 17: Analysis of single-cell clones of HEK-293 JF cells.
(A) Single-cell sort gates set up. Left – A representative histogram displaying negative
(peak at 102) and positive population (peak at 103) of HEK-293 cells transfected with
CRISPR constructs. Right - Cell sorter gates for single-cell sorting the positive iRFP-720
cells. Negative (P2) and positive (P3). P3 population was sorted into 96 well plates and
cultured for clone formation. (B) Table showing the percent of positive iRFP-720 cells
sorted from different transfection conditions and the number of viable clones after three
weeks in culture. (C) Imaging of HEK-293 JF cells obtained from the single-cell culture.
A viable clone from the TSC2 iRFP 720 Vector 3 and Guide 1 transfected in full serum
was seeded onto coverslips and stained with Tuberin antibody. The immunofluorescent
images depicting nuclei (blue), stained endogenous Tuberin (green) and Tuberin iRFP 720
(red) at 20x objective.
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DISCUSSION
The transition between G2 and mitosis during the cell cycle of mammalian cells
has been understudied compared to the other parts of the cell cycle (Lim and Kaldis, 2013).
The current understanding of this rapid and irreversible switch to mitosis is that this results
from a positive feedback loop, where activation of the Cyclin B1-CDK1 complex allows
CDK1 to further inactivate its inhibitors, Wee1 and Myt1, from phosphorylating CDK1 at
the end of G2. Increased nuclear import of the Cyclin B1-CDK1 complex also further
exacerbates the phosphorylation of the complex and leads to its full activation. However,
events leading up to this switch still need to be investigated further.
Our lab has characterized the formation of the Tuberin/Cyclin B1 complex and
elucidated how Tuberin regulates the localization of Cyclin B1during the G2/M transition
(Fidalgo da Silva et al., 2011). Decreased Tuberin/Cyclin B1 complex formation was
observed in the presence of a known Tuberin clinical mutant, Tuberin C696Y, and it has
been shown to increase mitotic onset (Nellist, 2001; Fidalgo da Silva et al., 2011). We have
also shown that this is a nutrient-sensitive interaction. Specifically, in the event of high
nutrients, phosphorylation of Tuberin by Akt enhances the Tuberin-Cyclin B1 binding and
prolongs the length of time in G2. On the other hand, using previously characterized Cyclin
B1 CRS variants, 5A (mainly cytoplasmic, delayed mitotic onset) and 5E (mainly nuclear,
enhanced mitotic onset), we have shown that Tuberin’s binding affinity to Cyclin B1 5A
is much greater than to Cyclin B1 5E. Given that Tuberin can still bind to Cyclin B1 5E, a
question arises regarding the timing of when Tuberin releases Cyclin B1 from its hold and
allow Cyclin B1 to accumulate in the nucleus to initiate mitosis. This thesis aims to
determine the role of the phosphorylation sites in the CRS region of Cyclin B1 for the
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Tuberin/Cyclin B1 complex formation and to create fluorescent tools to ultimately dissect
the interaction of this complex during the G2/M transition.
I.

Analysis of Cyclin B1 on the stabilization of Tuberin protein
Previously unpublished work in our lab has shown that Cyclin B1 may also have

an effect on the stability of the Tuberin protein. Tuberin protein levels were consistently
higher when Tuberin WT was co-transfected with Cyclin B1 compared to cells only
overexpressing Tuberin. Protein expression of Tuberin mutants, (that have a decreased
binding to Cyclin B1) is also lower when compared to the expression of Tuberin WT. So,
we questioned whether Cyclin B1 itself might affect the stabilization and localization of
Tuberin. To assess this, we used a clinically relevant Tuberin mutant, C696Y. To reiterate,
this Tuberin mutant has decreased binding affinity to Cyclin B1 and causes this cyclin to
localize in the nucleus more than when Cyclin B1 is co-transfected with Tuberin WT
(Fidalgo da Silva et al., 2011). Interestingly, this mutant also significantly translocates to
the nucleus (p<0.05) (Figure 5). In cell fractionation experiments, Tuberin is mainly
cytoplasmic in G1 through mitosis and is enriched in the nucleus at G0 phase of the cell
cycle (Rosner et al., 2007b). This study also found that Akt phosphorylation at S939 and
T1462 on Tuberin inhibits Tuberin’s nuclear localization. Tuberin-C696Y has also been
shown to have reduced phosphorylation by Akt (Nellist et al., 2005). Thus, the nuclear
localization of this mutant can be in part be explained by Akt’s inability to phosphorylate
it. It is not clear if Cyclin B1 has any role in the nuclear translocation of TSC2-C696Y
mutant protein. However, for future experiments, cell fractionation experiments with
overexpressed Tuberin with and without Cyclin B1 should be done to further quantify the
localization of Tuberin to address whether Cyclin B1 affects Tuberin localization.
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To address whether Tuberin protein levels are increased when co-transfected with
Cyclin B1, we chose to co-transfect Tuberin with increasing amounts of Cyclin B1 5A, as
demonstrated before (Fidalgo da Silva et al., 2011) this phospho-null cyclin binds stronger
to Tuberin than the wild-type or phosphomimetic Cyclin B1 5E (Figure 6). Linear
regression of 4 trials shows that there is no correlation between increasing the amount of
Cyclin B1 5A transfected and amount of Tuberin protein expressed (Figure 6B). We also
tried to address this question by treating the cells with MG132, a proteasome inhibitor, the
results were inconclusive (not shown). Instead of blocking the degradation of proteins in
the cell, we attempted an opposite approach, to inhibit protein synthesis by cycloheximide
(CHX) treatment. This treatment has been done in HEK-293 cells at 40 ng/mL of CHX to
determine Tuberin degradation effects (Chong-Kopera et al., 2006; Hu et al., 2008; Qin et
al., 2016). Their results show the half-life of Tuberin was between 2 – 4 hours with CHX
treatment. Despite many attempts, CHX treatment from 0 h to 12 h time points did not
result in decreasing levels of Tuberin protein in our experimental conditions. As a positive
control for the experiment, we measured the levels of p53 during the CHX treatment. p53
levels had a marked decrease at 4 hours of treatment when analyzing the lysate using
western blot techniques. In the literature, the half-life of p53 is 0.5 hours (Lukashchuk and
Vousden, 2007). Treating HEK-293 cells for 24 hours caused cell death. To further
troubleshoot our experimental conditions, HEPES was also added to maintain the cell
culture medium at the ideal pH for CHX activity, as per the following protocol (Kao et al.,
2015). CHX solution was also made fresh the day of the experiment, yet p53 levels did not
decrease as expected. Since the MG132 and CHX experiments failed to demonstrate any
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effect in protein degradation and protein synthesis, respectively, we cannot conclude that
Cyclin B1 has a role in Tuberin stability, and more studies need to be done.
II.

Effects of the phosphorylation of Cyclin B1 CRS domain on the
formation of the Tuberin/Cyclin B1 complex
A series of Cyclin B1 CRS variants were created to determine the essentiality of

the phosphorylation of the five serine residues in relation to Tuberin binding and how the
phosphorylation status affects the mitotic onset. The five phosphorylation sites: S116,
S126, S128, S133, and S147, were initially determined to be analogous to the four
phosphorylation sites on the X. laevis Cyclin B1 found to dictate Cyclin B1 cytoplasmic
localization (Hagting et al., 1999). This study aligned the CRS sequence of human, X.
laevis, and sea urchin Arbacia punctulate by eye. They also created mutants for each of the
five serine residues where they mutated the serine residues to threonine residues. Using
immunoprecipitation experiment, they pulled down the Cyclin B1 mutants from G2/M
phase HeLa cell extracts and assayed the Cyclin B1 phosphorylation in vitro. They found
that each of the five residues were phosphorylated, with S126 being the most heavily
phosphorylated.
To verify the importance of each one of these phosphorylation residues for the
Tuberin/Cyclin B1 complex, we compared the conservation of these residues between
species. We wanted to compare the homology of human Cyclin B1 with D. melanogaster,
D. rerio, X. laevis, and M. musculus using Clustal Omega (Figure 7). We found that only
S126 and S147 are perfectly aligned among these five organisms. While S133 was weakly
aligned, S128 was perfectly aligned in X. laevis, humans, and M. musculus. For S116, it is
substituted with a cysteine (C) in X. laevis, histidine (H) in D. rerio and a threonine (T) in
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D. melanogaster. The importance of the CRS is highlighted by its primary sequence which
is rich in prolines, making it a very flexible region of the protein (Williamson, 1994) and
proline-recognition domains are commonly used in cell signalling (Zarrinpar et al., 2003).
The different status of homology suggests that these residues have specific roles in the CRS
region.
We mutated each residue successively to determine which residue or residues
would be essential for the binding of Cyclin B1 to Tuberin. A schematic of the successive
mutation of the various Cyclin B1 CRS variants is shown in Figure 8A, the plasmid maps
in Figure 8B and the construction of each of the Cyclin B1 CRS variants created for this
thesis are as shown in Figure 8C. The constructs were successfully overexpressed in HEK293 cells (Figure 8D). Tuberin protein levels were also quantified to determine if there
were changes in levels with the various CRS variants, especially between Cyclin B1 5A
and Cyclin B1 5E (Figure 8E). We observed that 4A and 5E have higher Tuberin protein
levels (although not statistically significant), which contradicts our hypothesis that
increased Cyclin B1 binding causes increased Tuberin protein stability. One possibility is
that at these experimental conditions the Tuberin/Cyclin B1 complex is not being formed
and we do not see alteration of protein levels. Immunoprecipitation techniques was used to
assess the binding of Tuberin to the Cyclin B1 CRS variants: 5A; 4A; 3A; 1A and 5E
(Figure 9). Tuberin binding to Cyclin B1 decreases as the phosphorylation status of the
CRS increase, with the exception of 1A. However, more trials need to be conducted and
with the full set of variants to determine if this trial is an outlier.
Immunofluorescence techniques were used to measure mitotic onset when
Tuberin was co-transfected with the CRS phosphorylation mutants (Figure 10). We observe
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that the levels of mitotic onset obtained with Cyclin B1 5E is higher than the one obtained
with 5A, in concordance to our previously published results (Fidalgo da Silva et al., 2011).
This assured us that analysis could be conducted on the results obtained with the other
variants. The upstream regulator of S116 is unknown and is only conserved in humans and
M. musculus. Interestingly our results show that Cyclin B1 1A (S116 mutated to Alanine)
show a similar percentage of mitotic cells as the Cyclin B1 5E (Figure 10B), this confirms
that the phosphorylation of this residue does not play an important role for the
Tuberin/Cyclin B1 complex formation. Research by Toyoshima et al., demonstrated that
Cyclin B1 is still largely cytoplasmic when S133 and S147 residues (PLK1
phosphorylation sites) are mutated to Alanine (A). This agrees with our results where the
Cyclin B1 3A (S126, 128E) shows a reduced mitotic index when compared with the Cyclin
1A and 5E. When they mutated S126 and S128 (CDK1 phosphorylation sites) to alanine
(A), they found that cytoplasmatic localization occurred but not nuclear Cyclin B1
accumulation during prophase. Our results and theirs show the importance of the PLK1
and CDK1 phosphorylation to the nuclear translocation of Cyclin B1(Fidalgo da Silva et
al., 2011). Recently, it has been reported that PLK1 phosphorylates Hamartin promoting
the dissociation of the TSC complex leading to mTOR activation during mitosis (Li et al.,
2018). Tuberin is unstable without Hamartin (Chong-Kopera et al., 2006) and possibly
unable to bind to Cyclin B1 in this condition, suggesting that the PLK1 is playing a dual
role in the translocation of Cyclin B1 to the nucleus.
The Cyclin B1 CRS variants tagged with GFP constructed during this thesis's
development are an important tool to dissect the mechanism of mitotic onset controlled by
Tuberin. It can be used in immunofluorescence imaging to determine cellular localization
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and used in flow cytometry to determine their cell cycle profile and the percent of mitotic
cells. Also, further assays can be done in combination with the G2/M reporter vector
developed in our lab (Fidalgo da Silva et al., 2016) by both immunofluorescence and flow
cytometry. These constructs will also be used together in live-cell experiments to determine
the timing of mitotic entry in the presence or absence of over-expression of Tuberin WT
and Tuberin clinical mutants constructed in our lab.
III.

Construction of HEK-293 JF cell line
To better understand the role of Tuberin at the G2/M transition and other cellular

pathways, such as DNA damage, autophagy, and senescence, without overexpressing
Tuberin with a tag, we inserted a FP tag into the genome of HEK-293 cells using
CRISPR/Cas technique. This allows us to monitor Tuberin functions in vitro and in vivo
by fluorescence imaging more efficiently and eliminate the effects of endogenous Tuberin
that remains when using over-expressed proteins. This is of particular interest, as there are
several clinically relevant Tuberin mutants in our lab that have yet to be characterized.
CRISPR/Cas is a genome editing technique that was recently established (Ran et
al., 2013), and there are still much troubleshooting to be done when using this technique to
insert tags into the genome. To increase the probability of success, we designed many
guides and templates to insert iRFP 720 into the human genome. (Figure 11 - 15).
Puromycin treatments and passaging of the cell line verified that HEK-293 cells transfected
with only the constructed vectors emitted no iRFP 720 signal. Our flow cytometry and
imaging results have demonstrated that the iRFP 720 tag was successfully inserted into the
genome of HEK-293 cells. Using flow cytometry, we determined that different transfection
conditions for the guide vectors and amount of template produced different levels of
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fluorescence, meaning different efficiency of HDR (Figure 16C). The TSC2 gene is 60 bp
upstream of the PKD1 gene in a tail-to-tail orientation (Figure 11A). Large deletions in
TSC2 are known to cause TSC2/PKD1 contiguous gene deletion syndrome which lead to
the formation of renal cysts (Oyazato et al., 2011). It is necessary to have the clones of this
new cell line (HEK-293 JF) sent for whole genome sequencing to ensure that the iRFP 720
tag does not interfere with the PKD1 gene and that there are no off-target insertions that
are common with CRISPR constructs (Zhang et al., 2015). As observed in Figure 16B and
16C, we have a percentage of approximately 90 - 95% of cells that do not have the iRFP
720 fluorescence. The best efficiency was obtained with Vector 2 Guide 1 using serum
starvation and equal amounts of gRNA plasmid and donor template plasmid. To have a
pure population of HEK-293 JF cells, we performed single-cell sorting of the positive iRFP
720 population (Figure 17), and the single cells were cultured until enough cells were
grown to use for experiments and freeze-down stocks.
As shown in Figure 17C, the localization of TSC2-iRFP 720 presents a punctate
phenotype. This may be because the FP tag is an oligomeric FP which have been shown to
artificially aggregate their linked protein and alter the protein’s activity (Wannier et al.,
2018). Monomeric FP are more ideal for biological cell applications. The same research
group recently published a monomeric version of the iRFP 720 FP, miRFP720 (Matlashov
et al., 2020). This monomeric FP can act as a FRET pair with miRFP670 (Shcherbakova
et al., 2018). As a future experiment, a HEK-293 cell created with a Cyclin B1 tagged with
a miRFP670 FP and a Tuberin tagged with miRFP720 FP cell line could be created to allow
us to determine specific details of the Tuberin/Cyclin B1 complex that possibly cannot be
obtained with our actual over-expressed constructs.
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In summary, we have established conditions to use CRISPR technique for
insertion of fluorescent tags into the genome and successfully inserted a fluorescence tag
into the genome of HEK-293 cells, creating a HEK-293JF cell line. This new cell line
expresses iRFP 720 protein tagged to Tuberin. We have three clones of this cell line, and
our next steps will be to confirm the absence of off-target insertions in these clones, so they
will be ready to be used in future experiments. Also, these clones should be further
characterized by determining whether there are changes in the activity of Tuberin through
western blotting of key markers of mTOR activity, flow cytometry analysis to determine if
there are changes in cell cycle profile, and co-immunoprecipitation experiments to
determine if interaction to known binding proteins are altered.
Overall, the tools developed herein will allow us to answer specific questions with
regards to how Tuberin and Cyclin B1 interact to regulate mitotic onset, and perhaps
discover new roles that Tuberin may play in diverse cell pathways. These fluorescent
constructs can be used in model organisms, such as mouse and zebrafish, to monitor tumour
formation, migration, and cell adhesion. As well as used for testing or developing drugs for
the treatment of proliferative diseases as Tuberous Sclerosis Complex and cancers.
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APPENDICES
Appendix 1
Assessing Tuberin’s role in the event of double stranded DNA breaks
Tuberin is a multi-faceted protein that has a role in regulating cell growth and
division. The binding of Tuberin to Cyclin B1 is critical in preventing premature mitotic
onset. In the event of DNA damage, differential Cyclin B1 localization aids in preventing
mitosis from occurring. It is the nuclear localization of Cyclin B1 that allow cells to enter
mitosis when DNA damage is repaired, while ectopic Cyclin B1 nuclear localization when
the damage is still present causes apoptosis (Jin et al., 1998; Porter et al., 2003).
Interestingly, Tuberin also has a role in the cells’ sensitivity to DNA damage. In
fibroblasts with mutant Tuberin, nuclear-shuttling of the important double stranded break
stress factor, ATM is delayed (Ferlazzo et al., 2017). ATM shuttling delay prevents
recognition of double-stranded breaks by subsequent proteins. ATM functions to
phosphorylate the double-stranded break marker, H2AX histone, thereby allowing for its
relocating to the nucleus and recognize the double-stranded breaks
To determine the effects of overexpressed Tuberin on the cell cycle profile in the
event of DNA damage, a dose curve was constructed to determine the etoposide dose that
causes the death of 50% of NIH 3T3 cells after 24 hours of treatment (Appendix 1A). At 1
µM of etoposide, 20 percent of cells were dead as opposed to 2 µM concentration where
58 % of the cells died. NIH 3T3 cells were then transiently transfected with Tuberin WT
or the empty vector (mock) as the control and treated with 1 µM etoposide for 24 hours
then collected for cell cycle profile analysis (Appendix 1B). The left panel represents 0
hours of etoposide treatment, there was no significant difference in the percentage of G1
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and dead cells, however Tuberin overexpression had significantly increased number of
cells in G2/M than the mock. The right panel shows the percentage of cells in G1 phase,
G2/M phase and those that are dead. With Tuberin overexpression, there was a significant
increase in the percentage of overexpressed Tuberin cells were observed at the G2/M
compared to the control, in addition to less cell death.
A shorter time course experiment was performed to determine when cell death of
Tuberin overexpressing cells reaches a peak during the 24 hours of etoposide treatment.
The cells were collected and fixed at 0, 2, 4, 6, 8 hours of etoposide treatment (Appendix
3C). Due to large errors, there was no significant difference found between the control and
Tuberin overexpression cells. Interestingly, despite the large errors for the short timecourse experiment, the percentage of dead cells in the control reached an average of 20%
across the three trials by the 8-hour mark as opposed to 5 % in the Tuberin overexpressing
cells. Consistently across the timepoints, Tuberin overexpression resulted in increased
G2/M arrest than control. This evidence supports the hypothesis that Tuberin
overexpression aids in G2/M arrest, thereby allowing for DNA damage repair to take place
and avoid DNA damage induced cell death.
For future experiments, immunofluorescence techniques could be used to assess the
amount of DNA damage that occurred at each of these time points using Gamma-H2AX,
a marker for double-stranded breaks. In addition, live cell microscopy to determine the
length of G2/M in Tuberin overexpressing cells versus control cells.
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Appendix 1: Assessing cell cycle profile of etoposide treatment with Tuberin
overexpression in NIH 3T3 cells.
(A) Graph depicting etoposide dose curve from 0 to 10 µM. The lethal dose to kill 50%
of the NIH 3T3 is between 1 μM to 2 μM. n=1 (B) Significant difference in the percent of
cells arrested at G2/M of NIH 3T3 cells overexpressed with Tuberin WT versus pCMV
empty vector (Mock) as the control. NIH 3T3 cells were transfected with Tuberin WT
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and pCMV empty vector. 24 hours post-transfection, the cells were treated with 1 μM of
etoposide for 24 hours and collected for cell cycle profile analysis. NIH 3T3 cells
collected at 0 hours of etoposide treatment, showing a significant increase in the
percentage of overexpressed Tuberin cells in G2/M of the cell cycle (Left Panel). NIH
3T3 cells collected 24 post etoposide treatment, showing significant difference at the G1,
G2/M and dead cells between overexpressed and control sample (Right Panel). (C) An 8
hour treatment of etoposide that was collected for cell cycle profile analysis. NIH 3T3
cells at G2/M phase of the cell cycle comparing overexpressed Tuberin cells versus
control (Left Panel). Dead NIH 3T3 cells, comparing overexpressed Tuberin and control
(Right Panel). (* p<0.05) Statistical significance was determined using the Student’s
Unpaired t-test.
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Appendix 2
Construction of a fluorescent Tuberin WT plasmid, pHIV-TSC2 WT-dTomato, to visualize
Tuberin localization.
A Tuberin fluorescent tool was developed to complement the Cyclin B1 CRS
variant GFP vectors to determine how changes in Tuberin-Cyclin B1 interaction can affect
the localization of Tuberin throughout the cell cycle. This was created prior to the
construction of the CRISPR TSC2-iRFP 720 plasmid template vectors. We utilized cloning
techniques to construct a lentiviral vector, pHIV-TSC2 WT-dTomato. We began by
digesting the backbone vector, the mammalian DNA plasmid pHIV-dTomato from Bryan
Welm (Addgene plasmid #21374) (unpublished) with BamHI. We derived the TSC2 WT
sequence from pCMV Mlu- FLAG-TSC2 WT by digesting it with BamHI as well. This
piece was ligated to the backbone. Successful clones were screened by digesting the vectors
using BamH1 and confirmed by DNA sequencing with the upstream EF-1α promoter
(Eurofins).
After completion of this vector, it was then packaged into lentivirus and infected
into HEK-293 cells. After several attempts, a stable cell line with Tuberin WT-dTomato
could not be generated. A previous Master’s student, Ellen Laurie, created a ALDH1A1dTomato plasmid with this backbone vector and also had technical difficulties with the low
expression of dTomato even as an empty vector. This was confirmed by flow cytometry
and confocal microscopy (Laurie, 2018).
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Appendix 2: Molecular cloning of fluorescent Tuberin vector, pHIV-TSC2 WTdTomato.
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(A) pHIV-dTomato was utilized as the parent vector (Addgene plasmid # 21374) (B)
pCMV-FLAG-TSC2 WT was used to extract the TSC2 WT gene and ligate to the parent
vector. (C) Ligation clones were digested with BamHI to assess successful ligation. (D)
Vector map of pHIV-TSC2 WT-dTomato.
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Appendix 3
Table 3: PCR conditions and cycling conditions for successful amplification of
homologue arms for CRISPR donor vector
PCR Product

Template Amount

Cycling Conditions

Vector 2
5’ Homologue
Arm

560 ng of DNA

98℃ - 2 min
35 cycles:
- 98℃ - 10 sec
- 72℃ - 1.5 min
72℃ - 5 min
4˚C Hold

Vector 2
3’ Homologue
Arm

100 ng of DNA

98℃ - 2 min
35 cycles:
- 98℃ - 10 sec
- 72℃ - 1.5 min
72℃ - 5 min
4˚C Hold

Vector 3
5’ Homologue
Arm

280 ng of DNA

Vector 3
3’ Homologue
Arm

100 ng of DNA

98℃ - 1 min
35 cycles:
- 98℃ - 30 sec
- 72℃ - 1.5 min
72℃ - 5 min
4˚C Hold
98℃ - 2 min
35 cycles:
- 98℃ - 10 sec
- 72℃ - 1.5 min
72℃ - 5 min
4˚C Hold
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Yes
Yes

No
No
No
No
Yes
Yes

No
No
No
No
Yes
Yes
Yes
Yes

No

Tuberin + 1A - Mock + Tuberin
Tuberin + 5E - Mock + Tuberin

Tuberin + 4A - Tuberin + 5A
Tuberin + 3A - Tuberin + 5A
Tuberin + 2A - Tuberin + 5A
Tuberin + 1A - Tuberin + 5A

Tuberin + 5E - Tuberin + 5A
Tuberin + 3A - Tuberin + 4A

Tuberin + 2A - Tuberin + 4A
Tuberin + 1A - Tuberin + 4A
Tuberin + 5E - Tuberin + 4A
Tuberin + 2A - Tuberin + 3A

Tuberin + 1A - Tuberin + 3A
Tuberin + 5E - Tuberin + 3A
Tuberin + 1A - Tuberin + 2A
Tuberin + 5E - Tuberin + 2A
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Tuberin + 5E - Tuberin + 1A

0.77

0.0004
0
0.0023
0.00001

0.07
0.92
0.11
1

0.00
0.04

0.72
0.89
0.85
0.09

0
0

1.17

1.63
1.9
1.69
1.97

0.67
1.14
1.32
0.96

1.6
0.7

1.21
0.85
0.82
1.38

1.88
2.18

1.15
1.11

0.87

1.15
1.34
1.13
1.31

0.44
0.83
0.97
0.62

1.14
0.49

0.85
0.58
0.53
0.98

1.34
1.56

0.79
0.72

1.57

2.3
2.68
2.53
2.95

1.02
1.55
1.8
1.5

2.26
0.99

1.73
1.24
1.26
1.94

2.63
3.06

1.68
1.71

2.34

1.99

0.15

0.49
0.64
0.52
0.68

-0.4
0.13
0.28
-0.04

0.47
-0.36

0.19
-0.17
-0.2
0.32

0.63
0.78

0.14
0.1

0.5

0.31

-0.14

0.14
0.3
0.12
0.27

-0.81
-0.18
-0.03
-0.48

0.13
-0.72

-0.16
-0.55
-0.64
-0.02

0.29
0.44

-0.24
-0.33

0.15

-0.07

0.45

0.83
0.99
0.93
1.08

0.02
0.44
0.59
0.4

0.82
-0.01

0.55
0.22
0.23
0.66

0.97
1.12

0.52
0.54

0.85

0.69

0.1

0.11
0.11
0.13
0.13

0.14
0.1
0.1
0.15

0.11
0.12

0.12
0.13
0.15
0.11

0.11
0.11

0.13
0.14

0.12

0.13

1.56

4.29
5.63
3.93
5.07

-2.91
1.24
2.74
-0.25

4.16
-3.07

1.65
-1.32
-1.41
2.82

5.63
7

1.12
0.73

4.35

2.46

3.4 The percent of mitotic cells in Tuberin + 1A group is 1.4
4.89

0.95
1.00

1.16

0.93

0.1
0.1

Tuberin + 3A - Mock + Tuberin No
Tuberin + 2A - Mock + Tuberin No

1.65

1.36

0.66
0.81

0.00

0.04
0.19

0.21

0.35
0.5

Yes

1.93
2.25

Tuberin + 4A - Mock + Tuberin

1.04
1.21

Tuberin + 5A - Mock + Tuberin No

1.42
1.65

0.02
0.00002

Yes
Yes

Tuberin + 1A - Mock
Tuberin + 5E - Mock

CRS variants

Significant (pvalue < 0.05) P-value Exponentiated estimate Lower 95% CI Upper 95% CI Estimate
Lower 95% CI Upper 95% CI Standard Error Statistic Interpretation of exponentiated estimate
No
0.22
0.76
0.53
1.07
-0.28
-0.63
0.07
0.12
-2.43
No
1
1.03
0.72
1.47
0.03
-0.33
0.38
0.12
0.24
No
0.43
1.25
0.9
1.72
0.22
-0.1
0.54
0.11
2.08
No
0.93
0.87
0.61
1.24
-0.14
-0.5
0.22
0.12
-1.19
No
0.90
0.84
0.55
1.27
-0.18
-0.59
0.24
0.14
-1.29

Table 4: Poisson Regression of the percentage of mitotic cells across various Cyclin B1

Coeffcient
Mock + Tuberin - Mock
Tuberin + 5A - Mock
Tuberin + 4A - Mock
Tuberin + 3A - Mock
Tuberin + 2A - Mock
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